Zhongxin Jingwei, December 13 On the morning of the 13th, Hong Kong stocks opened lower and moved lower, with the Hang Seng State-owned Enterprises Index and the Hang Seng Technology Index falling more than 1% intraday. As of midday, the Hang Seng Index was down 074% at 16252At 67 points, the Hang Seng China Enterprises Index fell 100% at 5558At 47 points, the Hang Seng Tech Index fell 082% at 369958 points.
Source: wind
On the disk, the industry sector is almost all green, with automobiles, health care, materials, real estate, consumer durables, etc. among the top decliners, and only technology hardware and ** are red. In terms of concept stocks, lottery, car-t, and industry 40. Smart homes, smart terminals, smart wearables, etc. led the rise; **Education, liquor, sporting goods, beer, leasing and sales rights, cement, etc. led the decline.
In terms of popularity, Hygeia Medical rose 524%, Xiaomi Group rose 185%, SMIC rose 024%；Oriental Selection fell 720%, Xpeng Motors fell 659%, Li Ning fell 314%, Meituan fell 254%, Li Auto fell 245%, WuXi Biologics fell 245%, Tencent Holdings fell 090%。
Pharmaceutical stocks fell, and Pharmacist Gang fell 4309%, CARsgen fell 2691%。On the news side, CARsgen announced on the evening of the 12th Beijing time that the company's subsidiary in the United States, Carsgen Therapeutics Corporation, received a notice from the U.S. Food and Drug Administration (FDA) on the evening of December 11, Beijing time, requesting the suspension of clinical trials of CT053, CT041 and CT071, waiting for the conclusion reached after inspection at the production base in Durham, North Carolina.
On the 13th, the relevant person in charge of CARsgen responded to Zhongxin Jingwei that (the FDA's above-mentioned notice) is not for the company's products, but mainly to put forward some places that need to be optimized by the US factory. "We are confident that we will complete (optimization) soon, provide the rectification plan to the FDA, and then maintain communication with the FDA and implement the rectification. The above-mentioned person said.
Ping An ** pointed out that in 2023, the Hong Kong market will be affected by the Federal Reserve's monetary policy and changes in internal and external economic expectations, and the performance of the high-dividend strategy will prevail throughout the year. Looking forward to 2024, the benchmark assumptions of the domestic and foreign environment are expected to improve, and the Hong Kong market will usher in better investment opportunities after three consecutive years. (Zhongxin Jingwei app).
The views in this article are for reference only and do not constitute investment advice. )
For more exciting content, please pay attention to the official WeChat of JWVIEW***